中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

The Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patient with Colorectal Cancer Has Completed the Enrollment of All Subjects

On June 13, 2022, Simcere Pharma (2096.HK) announced that a global multi-center pivotal Phase 3 clinical trial (PRESERVE1 study) of Trilaciclib, an in...

2022-06-13
Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO

The 2022 annual meeting of American Society of Clinical Oncology (ASCO) held in Chicago and online in June 3-7, 2022 (EST) is attracting global attent...

2022-06-07
Simcere Releases 2021 Environmental, Social and Governance (ESG) Report

On May 31, 2022, Simcere Pharmaceuticals (2096.HK) released the 2021 Environmental, Social and Governance (ESG) Report. This report comprehensively sh...

2022-06-07
SIM0335, Simcere's Investigational Drug for Psoriasis Entered Phase II Clinical Trial and has completed the first patient enrollment

On May 27, 2022, Simcere Pharmaceuticals (2096.HK) announced that, SIM0335 (CKBA ointment), an innovative chemical drug candidate developed in-house b...

2022-05-27
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.